帕金森病胃肠功能障碍的发展和新兴趋势:长达十年的图书法分析分析
Yujia Sun1,2,3,4, Haoyu Yang1,2,3, Junfeng Zhang5
1The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Frontiers in aging neuroscience
|December 15, 2025
概括
胃肠道功能障碍是帕金森病的一个关键症状. 研究显示,越来越多的出版物关于其病变发生,临床问题,如便秘,和治疗,如便微生物群移植.
科学领域:
- 神经学 神经学
- 胃肠病学 胃肠病学
- 图书统计学 图书统计学
背景情况:
- 胃肠道 (GI) 功能障碍是帕金森病 (PD) 的常见非运动症状.
- 它显著影响疾病的进展和患者的生活质量.
- 在过去的十年里,研究肠胃功能障碍在PD中的研究已经大幅增长.
研究的目的:
- 系统地分析胃肠道功能障碍和PD研究的知识框架和不断变化的趋势.
- 确定关键的研究前沿,有影响力的出版物和合作模式.
- 为未来的研究和临床实践提供见解.
主要方法:
- 从网络科学核心收藏 (WoSCC) 中对2015年至2025年间发表的924篇文章进行了图书统计分析.
- 使用VOSviewer,CiteSpace和Bibliometrix进行并发,聚类和协作网络分析.
- 验证使用PubMed数据库进行关键字分析.
主要成果:
- 观察到出版物输出的年度增长是一致的.
- 中国和美国是最多产的国家,美国的引用率最高.
- 关键的研究领域包括致病性 (α-synuclein,脑-肠-微生物组轴),临床表现 (腹,便秘) 和疗法 (便微生物移植,益生菌).
结论:
- 图书统计分析显示,肠道功能障碍和病理病的研究领域日益发展.
- 该研究确定了主要的研究前沿和趋势,突出了病变发生,临床症状和治疗干预措施.
- 这些发现为未来的研究方向和帕金森病中胃肠道问题的临床管理提供了指导.
相关概念视频
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Parkinson's Disease: Treatment
940
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
940
Gastrointestinal Motility Disorders
1.0K
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
1.0K
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
614
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
614
Pharmacodynamics in Geriatric Patients: Effects of Age
175
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
175

